Clinical trial · Observational
Novel MRI Techniques for Pancreatic Cancer
Novel Multi-parametric MRI Techniques for Assessment of Patients With Pancreatic Ductal Adenocarcinoma Before and During Neoadjuvant Therapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Enrollment and other trial activities have temporarily paused due to COVID-19 and are expected to resume in the future; This is not a suspension of IRB approval
Summary
Brief summary (as posted)
The purpose of this study is to optimize magnetic resonance imaging (MRI) sequences for imaging pancreatic ductal adenocarcinoma and correlate MRI biomarkers with the expression of the tumor suppressor gene SMAD4 and clinical outcomes with the goal of identifying which biomarkers are predictive of treatment response or non-response. This study will test magnetic resonance techniques on FDA approved clinical MRI machines in treatment-naïve patients with biopsy-proven PDAC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Ductal Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MRI | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Treatment Naïve PDAC Patients
- description
- Patient presenting with treatment-naïve, biopsy-proven pancreatic ductal adenocarcinoma (PDAC) who qualifies for neoadjuvant chemo-radiation therapy.
- interventionNames
- Diagnostic Test: MRI
Primary outcomes (3)
- measure
- Optimize the following multiparametric MRI sequences for imaging of Pancreatic ductal adenocarcinoma (PDAC)
- timeFrame
- Study Duration, an average of 1 year
- description
- Arterial Spin Labeling (ASL), Blood Oxygenation Level Dependent (BOLD), Magnetization Transfer (MT), and reduced field-of-view Diffusion Weighted Imaging (DWI, including low b-values for intravoxel incoherent motion measurements and high b-values for Diffusion Kurtosis analysis).
- measure
- Measure the biomarkers obtained with MRI in treatment-naïve patients with biopsy-proven PDAC
- timeFrame
- Study Duration, an average of 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult male or female patient 18 years of age or older; * Patient presenting with treatment-naïve, biopsy-proven pancreatic ductal adenocarcinoma (PDAC); * Patient qualifying for neoadjuvant chemo-radiation therapy; * Patient able and willing to participate in the study; * Patient must sign the informed consent form in order to participate after the nature of the study has been fully explained to them and any questions they might have are adequately answered. * eGFR levels greater than or equal to 30 mL/min/1.73m2 before contrast administration. Exclusion Criteria: * Patient previously-received or receiving treatment for PDAC at time of enrollment; * Inability to understand or follow study instructions * Diagnosed by a nutritionist with severe malnutrition; * Unintentional weight loss of 20% or more throughout study; * BMI of \< 18.5; * Patients with a contraindication to MRI examinations will be excluded from this study. * Pregnancy * Estimated Glomerular Filtration Rate (eGFR) levels \< 30 mL/min/1.73m2
References
Publications (0)
Data not yet available